Glenmark slides after US jury rejects challenge in Tarka case
This article was originally published in Scrip
Executive Summary
The share price of Glenmark Pharmaceuticals fell sharply on the Bombay Stock Exchange after a US jury rejected the firm's challenge against Sanofi-Aventis' patent on the hypertension drug, Tarka (trandolapril/verapamil HCl).